336 related articles for article (PubMed ID: 22421527)
1. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.
Roy A; Roberts I; Vyas P
Semin Fetal Neonatal Med; 2012 Aug; 17(4):196-201. PubMed ID: 22421527
[TBL] [Abstract][Full Text] [Related]
2. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
Bhatnagar N; Nizery L; Tunstall O; Vyas P; Roberts I
Curr Hematol Malig Rep; 2016 Oct; 11(5):333-41. PubMed ID: 27510823
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
Watanabe K
Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
[TBL] [Abstract][Full Text] [Related]
4. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
5. Complete blood count differences in a cohort of Down syndrome neonates with transient abnormal myelopoiesis screened for GATA1 pathogenic variants.
Orozco-Vela M; Corona-Rivera A; Cruz-Osorio RM; Mendoza-Maldonado L; Márquez-Mora A; Barba-Barba CC; Peña-Padilla C; Baldomero-López A; Bobadilla-Morales L; Corona-Rivera JR
Am J Med Genet A; 2020 Sep; 182(9):2085-2093. PubMed ID: 32681702
[TBL] [Abstract][Full Text] [Related]
6. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
[TBL] [Abstract][Full Text] [Related]
7. Transient abnormal myelopoiesis in neonates: GATA get the diagnosis.
Bombery M; Vergilio JA
Arch Pathol Lab Med; 2014 Oct; 138(10):1302-6. PubMed ID: 25268193
[TBL] [Abstract][Full Text] [Related]
8. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
9. Prominent megakaryocytic dysplasia after regression of transient abnormal myelopoiesis associated with GATA-1 mutation.
Anoop P; Atra A
J Pediatr Hematol Oncol; 2012 Nov; 34(8):640. PubMed ID: 23007419
[TBL] [Abstract][Full Text] [Related]
10. GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
Lum SH; Choong SS; Krishnan S; Mohamed Z; Ariffin H
Singapore Med J; 2016 Jun; 57(6):320-4. PubMed ID: 27353457
[TBL] [Abstract][Full Text] [Related]
11. Evolution of myeloid leukemia in children with Down syndrome.
Saida S
Int J Hematol; 2016 Apr; 103(4):365-72. PubMed ID: 26910243
[TBL] [Abstract][Full Text] [Related]
12. Haematopoietic development and leukaemia in Down syndrome.
Roberts I; Izraeli S
Br J Haematol; 2014 Dec; 167(5):587-99. PubMed ID: 25155832
[TBL] [Abstract][Full Text] [Related]
13. Hematological disorders in children with Down syndrome.
Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
[TBL] [Abstract][Full Text] [Related]
14. Clinical, cytogenetic, and molecular analyses of 17 neonates with transient abnormal myelopoiesis and nonconstitutional trisomy 21.
Yuzawa K; Terui K; Toki T; Kanezaki R; Kobayashi A; Sato T; Kamio T; Kudo K; Sasaki S; Endo M; Ozono S; Nomura K; Ito E
Pediatr Blood Cancer; 2020 Apr; 67(4):e28188. PubMed ID: 32020774
[TBL] [Abstract][Full Text] [Related]
15. Sensitive detection of GATA1 mutations using complementary DNA-based analysis for transient abnormal myelopoiesis associated with the Down syndrome.
Mizuta S; Yamane N; Mononobe S; Watanabe A; Kitamura R; Takahara T; Matsushima C; Yoshida A; Okamoto S; Tanaka K; Iwai A; Ikegawa A; Wada T; Usami I; Maihara T; Komai T; Heike T; Nishida Y; Kobayashi K
Int J Lab Hematol; 2022 Apr; 44(2):349-355. PubMed ID: 34761527
[TBL] [Abstract][Full Text] [Related]
16. [Myeloid proliferations related to Down syndrome].
Hasegawa D
Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
[TBL] [Abstract][Full Text] [Related]
17. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
18. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
Garnett C; Cruz Hernandez D; Vyas P
IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
[TBL] [Abstract][Full Text] [Related]
19. A neonate with a unique non-Down syndrome transient proliferative megakaryoblastic disease.
Bertrums EJ; Buijs A; van Grotel M; Dors N; de Rooij JD; de Haas V; Hopman S; Jongmans MC; Zwaan CM; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27667142
[TBL] [Abstract][Full Text] [Related]
20. Transient abnormal myelopoiesis in non-Down syndrome neonate.
Ohkawa T; Miyamoto S; Sugie M; Tomizawa D; Imai K; Nagasawa M; Morio T; Mizutani S; Takagi M
Pediatr Int; 2015; 57(1):e14-7. PubMed ID: 25711269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
